Esperion Therapeutics Stock News

ANN ARBOR, Mich., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that members of Esperion's management team will participate in the upcoming Morgan Stanley 19th Annual Globa

Esperion's sales following its twin therapy approval have been slow to develop.Esperion's products are entering a crowded marketplace with significant price competition.

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q2 2021 Results - Earnings Call Transcript

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 8.24% and -1.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Esperion Therapeutics (NASDAQ:ESPR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 138.66% over the past year to ($1.67), which bea

Many investors are taking advantage of short-squeeze stocks by buying heavily shorted stocks when trading at or near all-time lows. The post 7 Names That Could Be The Next Short-Squeeze Stocks appeare

ANN ARBOR, Mich., July 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on June 28, 2021, the Compensation Committee of Esperion's Board of Directors granted 31 new employees

Short-sellers who made a bet on Esperion Therapeutics Inc. ( ESPR , Financial) have done well during the past year, but is it time to cash out? While Experion's share price has been cut nearly $30 to

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding sh

-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space;  previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served a

- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascu

Esperion: A Change In Plans After A Disappointing Q1 Earnings

It was all about the earnings.

Esperion Therapeutics Inc (NASDAQ: ESPR) reported a first-quarter EPS loss of $3.50, compared to $2.84 a year ago, which missed the analyst consensus estimate of $2.52. The company reported quarte